国际标准期刊号: 2476-2024

诊断病理学:开放获取

开放获取

我们集团组织了 3000 多个全球系列会议 每年在美国、欧洲和美国举办的活动亚洲得到 1000 多个科学协会的支持 并出版了 700+ 开放获取期刊包含超过50000名知名人士、知名科学家担任编委会成员。

开放获取期刊获得更多读者和引用
700 种期刊 15,000,000 名读者 每份期刊 获得 25,000 多名读者

抽象的

Effects of All-Trans-Retinoic Acid on Endometrium Cancer Cell Culture (Ishikawa) Alone and Combined with Classic Chemotherapeutics

Ozlem Ozgür Gursoy, Ceren Yildiz Eren, Hulusi Goktug Gurer, Ayşe Tansu Koparal, Sabit Sinan Ozalp

Background: Endometrial cancer is the most common type of gynecological cancer encountered in developed countries. Combination therapy is a treatment method that combines more than one agent used in treatment. Today it is one of the most important weapons in cancer treatment. In this study, the aim was to examine the sole and combined effects of classical chemotherapeutics drugs and ATRA on Ishikawa cells in vitro.

Methods: To determine the effects of classical chemotherapeutics and ATRA on Ishikawa cells, MTT, DAPI staining, caspase-3 and real-time PCR analyses was performed.

Results: It was observed that the combination of classical chemotherapeutics+ATRA significantly decreased cell viability at all doses. DAPI staining showed apoptosis. In apoptotic cells, it was observed that the nuclei strangulated, divided into small pieces, and condensed. Caspase 3 activity increased in parallel with the increase in the doses of ATRA and other agents and these increases were statistically significant. It was observed that combined applications do not have a reduction effect on gene activations as much as single applications.

Conclusion: In this study, ATRA and other agents sole and in combination showed significant anticancer effects in MTT, DAPI Staining and Caspase-3 analyses in Ishikawa cells. In Real-Time PCR analysis, ATRA and other agents showed similar anticancer effects when applied alone. However, the same effect was not observed when agents combined and this is different from some results in the literature. Researching this subject with new studies will contribute to the literature.